Reprogramming of myeloid progenitors by the BCR-ABL oncogene
The constitutive tyrosine kinase activity of the BCR-ABL oncogene is central for the pathogenesis of chronic myeloid leukaemia (CML). Clinical treatment of CML with the kinase inhibitor Imatinib Mesylate (IM) is a fundamental success demonstrating disease addiction upon BCR-ABL activity. However, 15...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
University of Leeds
2017
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.739770 |